التفاصيل البيبلوغرافية
| العنوان: |
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. |
| المؤلفون: |
Lee, Cathryn T.1 (AUTHOR) cathryn.lee@bsd.uchicago.edu, Hao, Wei2 (AUTHOR), Burg, Cindy A.3 (AUTHOR), Best, Jennie3 (AUTHOR), Kolenic, Giselle E.2 (AUTHOR), Strek, Mary E.1 (AUTHOR) |
| المصدر: |
Respiratory Research. 6/21/2024, Vol. 25 Issue 1, p1-9. 9p. |
| مصطلحات موضوعية: |
*PULMONARY fibrosis, *IDIOPATHIC pulmonary fibrosis, *PROPORTIONAL hazards models, *INTERSTITIAL lung diseases, *TREATMENT effectiveness |
| مستخلص: |
Background: Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease (ILD) with a high mortality rate. The antifibrotic medications pirfenidone and nintedanib have been in use since 2014 for this disorder and are associated with improved rate of lung function decline. Less is known about their long-term outcomes outside of the clinical trial context. Methods: The Pulmonary Fibrosis Foundation Patient Registry was used for this study. Patients with an IPF diagnosis made within a year of enrollment were included. The treated group was defined as patients receiving either pirfenidone or nintedanib for at least 180 days. The untreated group did not have any record of antifibrotic use. Demographic data, comorbidities, serial lung function, hospitalization, and vital status data were collected from the registry database. The primary outcomes were transplant-free survival, time to first respiratory hospitalization, and time to 10% absolute FVC decline. Time-to-event analyses were performed utilizing Cox proportional hazards models and the log-rank test. Model covariates included age, gender, smoking history, baseline lung function, comorbidities, and oxygen use. Results: The registry contained 1212 patients with IPF; ultimately 288 patients met inclusion criteria for the treated group, and 101 patients were designated as untreated. Patients treated with antifibrotics were significantly younger (69.8 vs. 72.6 years, p = 0.008) and less likely to have smoked (61.1% ever smokers vs. 72.3% never smokers, p = 0.04). No significant differences were seen in race, gender, comorbidities, or baseline pulmonary function between groups. The primary outcome of transplant-free survival was not significantly different between the two groups (adjusted HR 0.799, 95% CI 0.534–1.197, p = 0.28). Time to respiratory hospitalization was significantly shorter in the treated group (adjusted HR 2.12, 95% CI 1.05–4.30, p = 0.04). No significant difference in time to pulmonary function decline was seen between groups. Conclusions: This multicenter study demonstrated 63% of newly diagnosed IPF patients had continuous antifibrotic usage. Antifibrotics were not associated with improved transplant-free survival or pulmonary function change but was associated with an increased hazard of respiratory hospitalization. Future studies should further investigate the role of antifibrotic therapy in clinically important outcomes in real-world patients with IPF and other progressive ILDs. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder